Genentech’s Profit Rises 12%

Genentech’s net income rose 12% as cancer drugs Rituxan and Avastin logged double-digit sales growth.

Posted on April 10th, 2008 by
Filed under: stock news

Leave a Reply

« Ethan Allen Points to Weak Demand Fantasy Injury Experts Cross Over »

  • Calendar